Burn Injuries
6
2
2
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 6 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
33%
1 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (6)
Turkish Adaptation and Validation of the Burnt Hand Outcome Tool (BHOT)
Dynamics of Dysbiosis in the Skin and Gut Microbiome of Burn Patients
A Mixed-methods Acceptability Study of ProACTive to Help Burns Patients Adjust to Changes to Appearance
Inspiratory Muscle Training in Burned Adults
Mepilex Ag Versus Silver Sulfadiazine in Children and Adults With Burn Injuries.
Testing an Innovative Biomarker: Expression of HIF-1α and Its Isoforms in the Blood and Skin Tissue of Major Burns